ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomes

Published:2019-01-29 Issue: Volume:13 Page:
ISSN:1754-6605
Container-title:ecancermedicalscience
language:
Short-container-title:ecancer

Author:

Joshi Amit,Pande Nikhil,Noronha Vanita,Patil Vijay,Kumar Rajiv,Chougule Anuradha,Vaishakhi Trivedi,Janu Amit,Mahajan Abhishek,Prabhash Kumar

Publisher

Ecancer Global Foundation

Subject

Cancer Research,Oncology

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uniqueness of lung cancer in Southeast Asia;The Lancet Regional Health - Southeast Asia;2024-08

2. Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence;Lung Cancer;2024-06

3. Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India;JCO Global Oncology;2024-02

4. Clinical outcomes of ROS1-positive non-small cell lung cancer with limited access to ROS1-tyrosine kinase inhibitors (TKIs): experience from an Indian tertiary referral centre;ecancermedicalscience;2024-01-15

5. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective;Pathology - Research and Practice;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP